IGM Biosciences, Inc.
NASDAQ Global SelectTotal Valuation
IGM Biosciences, Inc. carries a market capitalization of 77.50M, placing it among publicly traded companies globally. Its enterprise value stands at -36.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 77.50M |
| Enterprise Value | -36.09M |
Share Statistics
IGM Biosciences, Inc. currently has 60.19M shares outstanding.
| Shares Outstanding | 60.19M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.47, and the price-to-book ratio stands at -0.07.
| PE Ratio | N/A |
| PS Ratio | 0.47 |
| PB Ratio | -0.07 |
| P/TBV Ratio | 0.68 |
| P/FCF Ratio | -0.44 |
| P/OCF Ratio | -0.44 |
Enterprise Valuation
| EV / Sales | 284.56 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
IGM Biosciences, Inc. maintains a current ratio of 17.66, meaning it holds 17.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 17.66 |
| Quick Ratio | 17.21 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -24.07 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
IGM Biosciences, Inc.'s stock has declined approximately -89.6748% over the past 52 weeks. The 50-day moving average sits at 1.27, while the 200-day moving average is 3.58.
| Beta (5Y) | N/A |
| 52-Week Price Change | -89.6748% |
| 50-Day Moving Average | 1.27 |
| 200-Day Moving Average | 3.58 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, IGM Biosciences, Inc. generated 145.05M in revenue and converted that into -53.38M in net income, yielding earnings per share of -0.88. EBITDA reached -702,000.00, while operating income came in at -8.07M.
| Revenue | 145.05M |
| Gross Profit | N/A |
| Operating Income | -8.07M |
| Pretax Income | -53.38M |
| Net Income | -53.38M |
| EBITDA | -702,000.00 |
| EBIT | -8.07M |
| Earnings Per Share (EPS) | -0.88 |
Balance Sheet
Total book value stands at -971.74M, with working capital of 100.93M providing operational flexibility.
| Cash & Cash Equivalents | 104.31M |
| Total Debt | N/A |
| Net Debt | -30.65M |
| Equity (Book Value) | -971.74M |
| Book Value Per Share | -15.95 |
| Working Capital | 100.93M |
Cash Flow
IGM Biosciences, Inc. produced -156.51M in operating cash flow over the past twelve months. After subtracting -2.19M in capital expenditures, free cash flow totaled -158.70M - equivalent to -2.61 per share.
| Operating Cash Flow | -156.51M |
| Capital Expenditures | -2.19M |
| Free Cash Flow | -158.70M |
| FCF Per Share | -2.61 |
Margins
IGM Biosciences, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -5.57 and net profit margin of -36.80 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -5.57 |
| Pretax Margin | -36.80 |
| Profit Margin | -36.80 |
| EBITDA Margin | -0.48 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -2.40 |
| FCF Yield | -226.22 |
Scores
IGM Biosciences, Inc. posts an Altman Z-Score of -3.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.73 |